Products Categories
CAS No.: | 74103-07-4 |
---|---|
Name: | Toradol |
Molecular Structure: | |
Formula: | C15H13NO3 |
Molecular Weight: | 376.40 |
Synonyms: | Ketorolac Tromethamine;RS 37619;Ketorolac Trometamol; |
Melting Point: | 160-161 °C |
Boiling Point: | 493.2 °C at 760 mmHg |
Flash Point: | 252.1 °C |
Appearance: | crystalline |
Hazard Symbols: | T |
Risk Codes: | 25-36/37/38-23/24/25 |
Safety: | 26-45-36/37/39 |
Transport Information: | UN 2811 6.1/PG 3 |
PSA: | 146.01000 |
LogP: | 0.65210 |
Molecular Structure:
Molecular Formula: C19H24N2O6
Molecular Weight: 376.4037
IUPAC Name: 2-Amino-2-(hydroxymethyl)propane-1,3-diol; 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
Synonyms of Ketorolac Tromethamine (CAS NO.74103-07-4): Ketorolac tromethamine [USAN] ; (+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) ; Acular ; Acular LS ; Acular PF ; Acular preservative free ; Acuvail ; Godek ; Sprix ; Syntex ; Toradol ; Tromethamine ketorolac ; UNII-4EVE5946BQ ; 1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro, (+-)-, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)
CAS NO: 74103-07-4
Classification Code: Analgesic ; Analgesics ; Analgesics, non-narcotic ; Anti-Inflammatory Agents ; Anti-inflammatory agents, non-steroidal ; Antirheumatic Agents ; Cyclooxygenase inhibitors ; Drug / Therapeutic Agent ; Enzyme Inhibitors ; Human Data ; Peripheral Nervous System Agents ; Sensory System Agents
Melting point: 160-161 °C
H bond acceptors: 4
H bond donors: 1
Freely Rotating Bonds: 3
Polar Surface Area: 48.3 Å2
Flash Point: 252.1 °C
Enthalpy of Vaporization: 80.07 kJ/mol
Boiling Point: 493.2 °C at 760 mmHg
Vapour Pressure: 1.52E-10 mmHg at 25°C
Ketorolac Tromethamine (CAS NO.74103-07-4) is a pyrrolizine carboxylic acid derivative structurally related to indomethacin. So it often used as an analgesic, antipyretic (fever reducer), and anti-inflammatory which acts by inhibiting the bodily synthesis of prostaglandins.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
man | TDLo | intramuscular | 857ug/kg (0.857mg/kg) | CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" | Journal of Toxicology, Clinical Toxicology. Vol. 32, Pg. 305, 1994. |
man | TDLo | intramuscular | 858ug/kg (0.858mg/kg) | CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Annals of Pharmacotherpy. Vol. 26, Pg. 1237, 1992. |
man | TDLo | intramuscular | 4300ug/kg/8D- (4.3mg/kg) | KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" BLOOD: "CHANGES IN SERUM COMPOSITION (E.G., TP, BILIRUBIN, CHOLESTEROL)" | Clinical Nephrology. Vol. 44, Pg. 276, 1995. |
man | TDLo | intramuscular | 19853ug/kg/12 (19.853mg/kg) | KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" | Annals of Pharmacotherpy. Vol. 27, Pg. 1055, 1993. |
mouse | LD50 | intraperitoneal | 225mg/kg (225mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) SKIN AND APPENDAGES (SKIN): HAIR: OTHER BEHAVIORAL: ATAXIA | Toksikologicheskii Vestnik. Vol. (6), Pg. 41, 1999. |
mouse | LD50 | oral | 293mg/kg (293mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: ATAXIA SKIN AND APPENDAGES (SKIN): HAIR: OTHER | Toksikologicheskii Vestnik. Vol. (6), Pg. 41, 1999. |
rat | LD50 | oral | 189mg/kg (189mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: ATAXIA SKIN AND APPENDAGES (SKIN): HAIR: OTHER | Toksikologicheskii Vestnik. Vol. (6), Pg. 41, 1999. |
women | LDLo | intramuscular | 15mg/kg/6D-I (15mg/kg) | KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" | Archives of Internal Medicine. Vol. 153, Pg. 1000, 1993. |
women | TDLo | intramuscular | 600ug/kg (0.6mg/kg) | GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF ENDOCRINE PANCREAS | Archives of Internal Medicine. Vol. 158, Pg. 411, 1998. |
women | TDLo | intramuscular | 1200ug/kg (1.2mg/kg) | BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" LUNGS, THORAX, OR RESPIRATION: BRONCHIOLAR CONSTRICTION LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Southern Medical Journal. Vol. 87, Pg. 282, 1994. |
women | TDLo | intramuscular | 8400ug/kg/3D- (8.4mg/kg) | KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" | American Journal of Kidney Diseases. Vol. 24, Pg. 578, 1994. |
Hazard Codes: T
Risk Statements: 36/37/38-23/24/25
R36/37/38: Irritating to eyes, respiratory system and skin.
R23/24/25: Toxic by inhalation, in contact with skin and if swallowed.
Safety Statements: 26-45-36/37/39
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S45: In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
S36/37/39: Wear suitable protective clothing, gloves and eye/face protection.
RIDADR: UN 2811 6.1/PG 3
WGK Germany: 3
RTECS: UY7759900
HazardClass: 6.1(a)
PackingGroup: II
Ketorolac Tromethamine (CAS NO.74103-07-4) is irritating to eyes, respiratory system and skin, when you have to contact with it you should avoid contact with skin and eyes or wear suitable protective clothing, gloves and eye/face protection. And it is toxic by inhalation, in contact with skin and if swallowed. In case of accident or if you feel unwell, seek medical advice immediately.
The side effects associated with ketorolac are, gastrointestinal ulcers, bleeding and perforation; kidney failure; hemorrhage, and hypersensitivity reactions. So it should be used by controlling.
Ketorolac Tromethamine (CAS NO.74103-07-4) is not recommended for obstetric analgesia because it has not been adequately tested for obstetrical administration and has demonstrable fetal toxicity in laboratory animals. And it is not recommended for long-term chronic pain patients neither.However, Ketorolac Tromethamine has been co-administered with meperidine and morphine without apparent adverse effects on patients.